AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6614521 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-HCl (n = 10)
Number of subjects: 40
Study 6614521 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-CO2 (n = 10)
Number of subjects: 40
Study 6614521 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% etidocaine (n = 10)
Number of subjects: 40
Study 6614521 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine (n = 10)
Number of subjects: 40
Study 30933317 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga during treatment
Number of subjects: 29
Study 30933317 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga post-treatment
Number of subjects: 29
Study 30933317 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (mixed samples)
Number of subjects: 29
Study 30933317 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 29
Study 29396788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 30
Study 29396788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27545747 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Approach of Yoga Therapy (IAYT)
Number of subjects: 81
Study 27545747 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 81
Study 24588893 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth comprehensive cardiac rehabilitation program (24-week personalized text message program and access to a supporting website)
Number of subjects: 120
Study 24588893 — intervention group
Group type: COMPARATOR
Intervention: usual cardiac rehabilitation care
Number of subjects: 120
Study 24588893 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth comprehensive cardiac rehabilitation program
Number of subjects: 120
Study 22998339 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (noncaloric beverages provided at home for 1 year)
Number of subjects: 224
Study 22998339 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (Hispanic participants)
Number of subjects: 224
Study 22998339 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 224
Study 19879305 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia participants during VOT-based discrimination in noise
Number of subjects: 0
Study 19879305 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison subjects during VOT-based discrimination in noise
Number of subjects: 0
Study 19879305 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia participants and healthy comparison subjects during first syllable discrimination
Number of subjects: 0
Study 19879305 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia participants during POA-based discrimination in noise
Number of subjects: 0
Study 19879305 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia participants and healthy comparison subjects
Number of subjects: 0
Study 17566756 — intervention group
Group type: EXPERIMENTAL
Intervention: 830nm LED phototherapy
Number of subjects: 76
Study 17566756 — intervention group
Group type: EXPERIMENTAL
Intervention: 633nm LED phototherapy
Number of subjects: 76
Study 17566756 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 830 and 633nm LED phototherapy
Number of subjects: 76
Study 17566756 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment light
Number of subjects: 76
Study 16261778 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal (AS)
Number of subjects: 463
Study 16261778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-DISC (BD)
Number of subjects: 463
Study 16261778 — intervention group
Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 463
Study 12406522 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A)
Number of subjects: 10
Study 12406522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10090869 — intervention group
Group type: EXPERIMENTAL
Intervention: Media-led community education campaign
Number of subjects: 933
Study 10090869 — intervention group
Group type: COMPARATOR
Intervention: Control group (women in Los Angeles and Orange Counties)
Number of subjects: 933
Study 7562387 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31161241 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial (AM) technique
Number of subjects: 106
Study 31161241 — intervention group
Group type: COMPARATOR
Intervention: Transtibial (TT) technique
Number of subjects: 106
Study 28295414 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (not specified)
Number of subjects: 1383
Study 26442394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 0.5 mg.kg(‐1)
Number of subjects: 64
Study 26442394 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 64
Study 23561842 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental change intervention
Number of subjects: 179
Study 23561842 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 179
Study 17822764 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program (HFAK)
Number of subjects: 325
Study 17822764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visiting)
Number of subjects: 325
Study 16201937 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (500 mg IV q8h)
Number of subjects: 1076
Study 16201937 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (500 mg IV q8h)
Number of subjects: 1076
Study 16201937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1076
Study 12899226 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg doxazosin daily for 3 months
Number of subjects: 60
Study 12899226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10599899 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (3 hours/week for three months)
Number of subjects: 27
Study 10599899 — intervention group
Group type: COMPARATOR
Intervention: Usual activities of daily living (Control group)
Number of subjects: 27
Study 8566836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (ASA) 650 mg three times daily
Number of subjects: 20
Study 8566836 — intervention group
Group type: COMPARATOR
Intervention: Effervescent calcium carbasalate (ECC) 826.8 mg three times daily
Number of subjects: 20
Study 8566836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (ASA)
Number of subjects: 20
Study 8566836 — intervention group
Group type: COMPARATOR
Intervention: Effervescent calcium carbasalate (ECC)
Number of subjects: 20
Study 2011771 — intervention group
Group type: EXPERIMENTAL
Intervention: d-penicillamine (500 mg/day)
Number of subjects: 26
Study 2011771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2011771 — intervention group
Group type: EXPERIMENTAL
Intervention: d-penicillamine
Number of subjects: 26
Study 7091871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 ppm ozone exposure (O2)
Number of subjects: 25
Study 7091871 — intervention group
Group type: COMPARATOR
Intervention: Purified air (Control)
Number of subjects: 25
Study 31828275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 31828275 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 31828275 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 29981438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 27306620 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg apixaban twice daily (n=9120)
Number of subjects: 18201
Study 27306620 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR range 2.0-3.0; n=9081)
Number of subjects: 18201
Study 27306620 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 27306620 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 24992623 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Glucose Tolerance (NGT) at baseline
Number of subjects: 4566
Study 24992623 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes at baseline
Number of subjects: 4566
Study 24992623 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals maintaining NGT during follow-up
Number of subjects: 4566
Study 24992623 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals progressing to T2D from NGT or prediabetes
Number of subjects: 4566
Study 24992623 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals regressing from prediabetes to NGT
Number of subjects: 4566
Study 22912453 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CM
Number of subjects: 432
Study 22912453 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% LM
Number of subjects: 432
Study 22912453 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% CM + 2.5% LM (blend)
Number of subjects: 432
Study 22912453 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 432
Study 18678242 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week Mindfulness-based stress reduction (MBSR) program
Number of subjects: 48
Study 18678242 — intervention group
Group type: COMPARATOR
Intervention: 1-day control seminar
Number of subjects: 48
Study 18807583 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg tablet formulation A
Number of subjects: 20
Study 18807583 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 2.5 mg tablet formulation B
Number of subjects: 20
Study 16297323 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Glutathione (GSH) 1.2 g/d through intravenous drip for 7 days
Number of subjects: 45
Study 16297323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GSH)
Number of subjects: 45
Study 12117045 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1/FEV6
Number of subjects: 5887
Study 12117045 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1/FVC
Number of subjects: 5887
Study 10100041 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 84
Study 10100041 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + metronidazole tabs 200 mg tds for 7 days
Number of subjects: 84
Study 10100041 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 2 subgingival applications of 25% metronidazole gel
Number of subjects: 84
Study 10100041 — intervention group
Group type: COMPARATOR
Intervention: Control (non-smokers)
Number of subjects: 84
Study 10100041 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 84
Study 7748020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 53
Study 7748020 — intervention group
Group type: COMPARATOR
Intervention: Omnivorous diet (Control)
Number of subjects: 53
Study 2336545 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy and propranolol
Number of subjects: 29
Study 2336545 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy only
Number of subjects: 29
Study 85106 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay g 6575 (1.2 g daily for 1 week)
Number of subjects: 6
Study 85106 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay g 6575 (1.2 g single dose)
Number of subjects: 6
Study 85106 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay g 6575 and dipyridamole (combined administration)
Number of subjects: 6
Study 85106 — intervention group
Group type: COMPARATOR
Intervention: Dipyridamole (alone)
Number of subjects: 6
Study 85106 — intervention group
Group type: COMPARATOR
Intervention: Bay g 6575 (alone)
Number of subjects: 6
Study 31400765 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5% isomaltulose-electrolyte beverage
Number of subjects: 10
Study 31400765 — intervention group
Group type: COMPARATOR
Intervention: 2% isomaltulose (CHO-2%)
Number of subjects: 10
Study 31400765 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 29220860 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate in a randomized trial deferring resection of diminutive polyps until the next surveillance colonoscopy
Number of subjects: 557
Study 29220860 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to defer resection of diminutive polyps outside of a clinical trial
Number of subjects: 557
Study 29220860 — intervention group
Group type: COMPARATOR
Intervention: Factors associated with willingness to defer resection
Number of subjects: 557
Study 27583214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminobisphosphonate solution
Number of subjects: 24
Study 27583214 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 24
Study 25444700 — intervention group
Group type: EXPERIMENTAL
Intervention: Home perineal electrostimulation (HPES)
Number of subjects: 161
Study 25444700 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 161
Study 21890864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed height at mid-thigh
Number of subjects: 101
Study 21890864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed height at anterior superior iliac spine
Number of subjects: 101
Study 21890864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed height at xiphisternum
Number of subjects: 101
Study 20059657 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary repair without inflatable penile prosthesis (IPP)
Number of subjects: 26
Study 20059657 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive index (RI) cutoff of <0.80
Number of subjects: 26
Study 20059657 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile duplex ultrasonography (PDU)
Number of subjects: 26
Study 20059657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic infusion cavernosometry and cavernosography (DICC)
Number of subjects: 26
Study 17722961 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine
Number of subjects: 0
Study 15743729 — intervention group
Group type: COMPARATOR
Intervention: African-American children
Number of subjects: 222
Study 11753000 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg neostigmine administered upon reappearance of the first tactile TOF response (group I)
Number of subjects: 64
Study 11753000 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg neostigmine administered upon reappearance of the second tactile TOF response (group II)
Number of subjects: 64
Study 11753000 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg neostigmine administered upon reappearance of the third tactile TOF response (group III)
Number of subjects: 64
Study 11753000 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg neostigmine administered upon reappearance of the fourth tactile TOF response (group IV)
Number of subjects: 64
Study 11753000 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no neostigmine administration)
Number of subjects: 64
Study 10508797 — intervention group
Group type: EXPERIMENTAL
Intervention: MC(+) (n = 58) with a control unit measuring effective compliance
Number of subjects: 121
Study 10508797 — intervention group
Group type: COMPARATOR
Intervention: MC(−) (n = 63) without a control unit measuring effective compliance
Number of subjects: 121
Study 10508797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MC(+) and MC(−))
Number of subjects: 121
Study 10508797 — intervention group
Group type: COMPARATOR
Intervention: Previous study
Number of subjects: 121
Study 8834628 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to manganese
Number of subjects: 0
Study 8834628 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2283012 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2‐gel (Prepidil) intravaginal
Number of subjects: 30
Study 2283012 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 30
Study 7053334 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (nonsteroidal estrogen)
Number of subjects: 0
Study 7053334 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogens, orchiectomy, or both
Number of subjects: 0
Study 7053334 — intervention group
Group type: COMPARATOR
Intervention: Estrogen treatment
Number of subjects: 0
Study 30236471 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional supervised physical activity (median of 20 additional minutes per day for a median of 16.5 days)
Number of subjects: 198
Study 30236471 — intervention group
Group type: COMPARATOR
Intervention: Social activities (control group)
Number of subjects: 198
Study 30236471 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional supervised physical activity
Number of subjects: 198
Study 26957836 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor agents
Number of subjects: 0
Study 26957836 — intervention group
Group type: EXPERIMENTAL
Intervention: New pharmacologic agents
Number of subjects: 0
Study 24328907 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate 0.1% cream (BMVc)
Number of subjects: 20
Study 24328907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment (TACo)
Number of subjects: 20
Study 22521875 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg hydrocortisone given as a rapid intravenous bolus
Number of subjects: 14
Study 22521875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 20679600 — intervention group
Group type: EXPERIMENTAL
Intervention: SNR (Sentinel lymph node resection)
Number of subjects: 749
Study 20679600 — intervention group
Group type: COMPARATOR
Intervention: SNAD (SNR followed by axillary dissection)
Number of subjects: 749
Study 20679600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SNAD and SNR
Number of subjects: 749
Study 18187209 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial myofunctional evaluation with scores (OMES)
Number of subjects: 80
Study 18187209 — intervention group
Group type: COMPARATOR
Intervention: Traditional orofacial myofunctional evaluation (TOME)
Number of subjects: 80
Study 16328453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 degrees C cold pain stimulus
Number of subjects: 14
Study 16328453 — intervention group
Group type: EXPERIMENTAL
Intervention: intradermal injection of 50 microg capsaicin without cooling
Number of subjects: 14
Study 16328453 — intervention group
Group type: EXPERIMENTAL
Intervention: injection of capsaicin followed by application of 0 degrees C cold pain stimulation
Number of subjects: 14
Study 16328453 — intervention group
Group type: COMPARATOR
Intervention: 30 degrees C neutral stimulus
Number of subjects: 14
Study 14971086 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 0
Study 14971086 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 0
Study 10853874 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 2617
Study 10853874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2617
Study 8792266 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training
Number of subjects: 80
Study 8792266 — intervention group
Group type: COMPARATOR
Intervention: Listening to unmodified music
Number of subjects: 80
Study 1473164 — intervention group
Group type: EXPERIMENTAL
Intervention: Allylestrenol (30 mg/d initially, reduced to 5 mg/d after 15 days)
Number of subjects: 42
Study 1473164 — intervention group
Group type: EXPERIMENTAL
Intervention: Lynestrenol (10 mg/d initially, reduced to 1.25 mg/d)
Number of subjects: 42
Study 1473164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6143138 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of activity, anti-inflammatory and antirheumatic drugs, and systemic steroids where necessary
Number of subjects: 0
Study 6143138 — intervention group
Group type: COMPARATOR
Intervention: Rest and anti-inflammatory and antirheumatic drugs
Number of subjects: 0
Study 30559259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab (10 mg/kg test dose followed by 60 mg/kg full dose 1 to 4 days later and 3 additional weekly doses of 60 mg/kg)
Number of subjects: 10
Study 30324924 — intervention group
Group type: EXPERIMENTAL
Intervention: SAP P11-4
Number of subjects: 24
Study 30324924 — intervention group
Group type: COMPARATOR
Intervention: CPP-ACP (control)
Number of subjects: 24
Study 27797093 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Spinal Lidocaine (SS-L): 3 mL of 0.8% lidocaine solution (24 mg lidocaine, 15 μg fentanyl)
Number of subjects: 84
Study 27797093 — intervention group
Group type: COMPARATOR
Intervention: Conventional Dose Lidocaine (CD-L): 5 mL of 1% lidocaine solution (50 mg lidocaine, 25 μg fentanyl)
Number of subjects: 84
Study 25361563 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPPP treatment group
Number of subjects: 0
Study 22243622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand hygiene with soap and water
Number of subjects: 683
Study 22243622 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub
Number of subjects: 683
Study 22243622 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 683
Study 22243622 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and water
Number of subjects: 683
Study 19823863 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane blue
Number of subjects: 30
Study 19823863 — intervention group
Group type: COMPARATOR
Intervention: Infracyanine green
Number of subjects: 30
Study 18060250 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor IX aptamers
Number of subjects: 0
Study 18060250 — intervention group
Group type: EXPERIMENTAL
Intervention: Von Willebrand factor aptamers
Number of subjects: 0
Study 18060250 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic pharmacobiologic therapy
Number of subjects: 0
Study 16128945 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-weekly endoscopic variceal ligation (EVL)
Number of subjects: 63
Study 16128945 — intervention group
Group type: COMPARATOR
Intervention: Bi-monthly endoscopic variceal ligation (EVL)
Number of subjects: 63
Study 12401580 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus followed by a 4 mg/min infusion during operation and 4 mg/kg in the priming solution of CPB)
Number of subjects: 118